Researchers for a universal flu vaccine based on mRNA technology are beginning to enroll volunteers in an early-stage clinical trial.
The National Institute of Allergy and Infectious Diseases Vaccine Research Center has started to enroll volunteers at the Duke University for its Phase 1 trial of the mRNA-based vaccine, which uses the same technology as the COVID-19 vaccines. The study will have 50 “healthy volunteers” ages 18 to 49 enrolled in the trial who will receive check ups up to one year after their vaccination.